James P. Allison

121.0k citations
486 papers · 73.0k · 66 hit papers · h-index 125

Impact in

  • Immunology top 0.01%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction
    • T-cell and B-cell Immunology
    • Immune cells in cancer
  • Oncology top 0.01%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research

Papers in

    • Immunotherapy and Immune Responses 183
    • Immune Cell Function and Interaction 166
    • T-cell and B-cell Immunology 151
    • Cancer Immunotherapy and Biomarkers 180
    • CAR-T cell therapy research 81

James P. Allison

473 papers receiving 71.6k citations

James P. Allison's Hit Papers

Immune checkpoint therapy—current perspectives and future directions 2023 · 657 citations
6570+4+8Years since publication10002.0k3.0k

Peers

James P. Allison
Comparison fields: 5 of 190
  • Immunology 46.5k
  • Oncology 35.9k
  • Biological Psychiatry 603
  • Cancer Research 3.1k
  • Radiology, Nuclear Medicine and Imaging 4.4k
Replace Robert D. Schreiber with:
Robert D. Schreiber United States
Arlene H. Sharpe United States
Drew M. Pardoll United States
Mark J. Smyth Australia
Gordon J. Freeman United States
Jedd D. Wolchok United States
Hideo Yagita∥ Japan
Lieping Chen United States
Jacques Banchereau United States
Nicholas P. Restifo United States
James P. Allison relative to Robert D. Schreiber United States Robert D. Schreiber's profile →
Citations per field
00.5×1.5×
Robert D. Schreiber · 1×
Citations per year

Countries citing papers authored by James P. Allison

Since Specialization
Citations

This map shows the geographic impact of James P. Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James P. Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James P. Allison more than expected).

Fields of papers citing papers by James P. Allison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James P. Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James P. Allison. The network helps show where James P. Allison may publish in the future.

Co-authors

The 25 scholars most cited alongside James P. Allison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James P. Allison Line = papers co-authored together James P. Allison links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 486 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The future of immune checkpoint therapy
Hit paper breakdown →
20153647
2
Restoring function in exhausted CD8 T cells during chronic viral infection
Hit paper breakdown →
20053138
3
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Hit paper breakdown →
19962951
4
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Hit paper breakdown →
20182253
5
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Hit paper breakdown →
19951748
6
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Hit paper breakdown →
20151745
7
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Hit paper breakdown →
20101474
8
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
Hit paper breakdown →
19921359
9
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Hit paper breakdown →
20031235
10
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Hit paper breakdown →
20131110
11
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Hit paper breakdown →
20091059
12
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Hit paper breakdown →
1993977
13
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Hit paper breakdown →
2017951
14
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hit paper breakdown →
2012942
15
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Hit paper breakdown →
2016937
16
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
Hit paper breakdown →
2001834
17
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
Hit paper breakdown →
1999824
18
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
Hit paper breakdown →
2001805
19
Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
Hit paper breakdown →
2005792
20
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hit paper breakdown →
2003780

About James P. Allison

James P. Allison is a scholar working on Immunology, Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 486 papers that have together received 73.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (183 papers), Cancer Immunotherapy and Biomarkers (180 papers), Immune Cell Function and Interaction (166 papers), T-cell and B-cell Immunology (151 papers), CAR-T cell therapy research (81 papers), Monoclonal and Polyclonal Antibodies Research (37 papers), Behavioral and Psychological Studies (27 papers) and Diabetes and associated disorders (23 papers). The work is most often cited by research in Immunology (46.5k citations), Oncology (35.9k citations), Biological Psychiatry (603 citations), Cancer Research (3.1k citations) and Radiology, Nuclear Medicine and Imaging (4.4k citations). James P. Allison has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Padmanee Sharma, Matthew F. Krummel, Dana R. Leach, Cynthia A. Chambers, Jedd D. Wolchok, Spencer C. Wei, Karl S. Peggs, Colm R. Duffy, Jackson G. Egen and Wendy L. Havran. Their work appears in journals such as The Journal of Immunology, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Cancer Immunology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

You can learn more about the impact of James P. Allison by visiting their Pantheon page.

Explore authors with similar magnitude of impact